GlassScriptPhysician profile
Kerry Reller
NPI 1649513276
$8,124.73
in general payments reported to CMS, 2019-2025
34 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $507 · 2021: $850 · 2022: $919 · 2023: $1,496 · 2024: $1,350 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264 · Consulting Fee: $41.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.12 |
| Consulting Fee | $41.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,677.48 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,393.41 | 2019-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $972.70 | 2020-2025 | Hyqvia, Cuvitru, Glassia |
| Genzyme Corporation | $750.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $459.42 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $420.99 | 2019-2025 | |
| Csl Behring | $365.32 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novo Nordisk INC | $308.87 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $268.69 | 2022-2025 | Mounjaro, Zepbound, Ebglyss |
| Amgen INC. | $192.47 | 2021-2024 | Tezspire, Krystexxa |
| Pharming Healthcare, INC. | $179.73 | 2025 | Ruconest |
| Grifols USA, LLC | $131.68 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $124.95 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $124.10 | 2021-2022 | |
| Astellas Pharma US INC | $86.28 | 2024-2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Pfizer INC. | $78.90 | 2021-2025 | |
| Corcept Therapeutics | $65.47 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.55 | 2020-2022 | |
| Exact Sciences Corporation | $45.34 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $41.85 | 2021-2025 | |
| Adma Biomanufacturing LLC | $41.25 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $40.28 | 2022 | |
| Optinose US, INC. | $34.70 | 2024-2025 | |
| Lucid Diagnostics INC. | $22.38 | 2024 | |
| Verona Pharma, INC. | $21.42 | 2025 | Ohtuvayre |
| Gc Biopharma USA, INC. | $19.58 | 2025 | Alyglo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2025 | Zoryve |
| Incyte Corporation | $18.06 | 2022 | |
| Shire North American Group INC | $16.55 | 2019 | |
| Kaleo, INC. | $15.52 | 2022 | |
| Abbott Laboratories | $15.10 | 2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Reller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.